tiprankstipranks
Trending News
More News >

Replimune price target raised to $18 from $16 at JPMorgan

JPMorgan raised the firm’s price target on Replimune (REPL) to $18 from $16 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue